

Supplementary:

Figure A1: CONSORT diagram showing derivation of the study cohort




Figure A2: Overview of study design




Table A1: Top 25 medications used in ESRD patient cohort by class

ANTIPLATELET	CLOPIDOGREL
BETA BLOCKER	CARVEDILOL, METOPROLOL SUCCINATE, METOPROLOL TARTRATE
CALCIUM CHANNEL BLOCKER	AMLODIPINE BESYLATE, NIFEDIPINE
CALCIUM/CALCIMIMETICS	CINACALCET HCL, CALCIUM ACETATE
INSULIN	INSULIN GLARGINE
NARCOTICS	HYDROCODONE/ACETAMINOPHEN
PHOSPHATE BINDER	SEVELAMER CARBONATE
PROTON PUMP INHIBITOR	OMEPRAZOLE, PANTOPRAZOLE SODIUM
RAAS BLOCKER	LISINOPRIL
STATIN	SIMVASTATIN, ATORVASTATIN CALCIUM, PRAVASTATIN SODIUM
VASODILATOR	HYDRALAZINE HCL, NITROGLYCERIN, ISOSORBIDE MONONITRATE
ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	LOSARTAN POTASSIUM
DIURETICS	FUROSEMIDE
Other	GABAPENTIN, LEVOTHYROXINE SODIUM, CLONIDINE HCL

Table A2: Most frequently prescribed medications (top 10) ESRD patients taking on index date

Rank	Generic Names	COUNT	Percentage
1	CLOPIDOGREL BISULFATE	44280	95.1971
2	SEVELAMER CARBONATE	11533	24.7947
3	AMLODIPINE BESYLATE	11391	24.4894
4	CARVEDILOL	10938	23.5155
5	ATORVASTATIN CALCIUM	10683	22.9673

Rank	Generic Names	COUNT	Percentage
6	METOPROLOL TARTRATE	9404	20.2176
7	LISINOPRIL	9286	19.9639
8	CINACALCET HCL	8322	17.8914
9	SIMVASTATIN	8107	17.4292
10	CALCIUM ACETATE	8035	17.2744

Count indicates how many patients are on top 10 medications on index date. Percent indicates the percentage of the medication on all the medications but not our cohort size (N=46,514).